Zika virus RNA has been detected in semen collected several months after onset of symptoms of infection. Given the potential for sexual transmission of Zika virus and for serious fetal abnormalities resulting from infection during pregnancy, information regarding the persistence of Zika virus in semen is critical for advancing our understanding of potential risks. We tested serial semen samples from symptomatic male patients in the United Kingdom who had a diagnosis of imported Zika virus infection. Among the initial semen samples from 23 patients, Zika virus RNA was detected at high levels in 13 (56.5%) and was not detected in 9 (39.1%); detection was indeterminate in 1 sample (4.4%). After symptomatic infection, a substantial proportion of men have detectable Zika virus RNA at high copy numbers in semen during early convalescence, suggesting high risk for sexual transmission. Viral RNA clearance times are not consistent and can be prolonged.

Zika virus is an emerging flavivirus currently causing a major outbreak of human disease in the Americas, the Caribbean, and Western Pacific regions; 71 countries and territories have reported mosquito-borne transmission since 2015 (1). Human infection can be subclinical (2). Symptomatic infection usually causes a mild, self-limiting illness accompanied by rash, fever, arthralgia, and myalgia (2–5). However, international scientific consensus holds that Zika virus infection is a cause of 2 severe clinical sequelae recognized recently: Guillain-Barré syndrome and congenital neurologic abnormalities, including microcephaly (6). The risk for adverse obstetric outcome after maternal infection during pregnancy is currently unknown, but the risk for microcephaly attributable to Zika virus infection in the first trimester has been estimated to be 0.88%–13.2% (7).

Zika virus is primarily mosquito-borne, but sexual transmission has also been described (8–14). To date, 12 countries have reported non-vectorborne transmission (1), usually sexual transmission from men after symptomatic infection, although transmission after asymptomatic infection also has been described (15,16). Sexual transmission is a major concern for pregnant women and couples considering pregnancy because of the risk for adverse fetal sequelae. Information on Zika virus persistence in semen is required to inform public health guidance for the prevention of sexual transmission. With few exceptions (17,18), published data are mostly limited to individual case reports, and few publications report isolation of infectious Zika virus from semen. However, Zika virus RNA has been detected in semen up to 6 months after onset of symptoms (19,20). This potential for prolonged onward transmission warrants further investigation. We describe the analysis of serial semen samples from 23 symptomatic Zika virus–infected male travelers to determine the presence and persistence of Zika virus RNA.

Methods

Testing of Diagnostic Samples

We diagnosed possible imported Zika virus infection in patients by using a real-time reverse transcription PCR (rRT-PCR) assay based on a published method targeting the nonstructural protein 1 (NS1) gene (21) and a commercial serologic assay (EUROIMMUN AG, Lübeck, Germany). (We diagnosed infection in patient 1 by using a different rRT-PCR assay [22]). We performed viral RNA extraction on the EZ1 platform by using the EZ1 Virus Mini Kit with Buffer AVL (QIAGEN, Valencia, CA, USA) inactivated samples. We also tested all patients for other pathogens, such as chikungunya and dengue viruses, by using published molecular and commercial serologic assays. The preferred sample type was serum or plasma, but published testing guidance specifically called for urine samples from pregnant women and male partners of pregnant women.

Testing of Semen Samples

We offered a Zika virus RNA semen testing service to adult male patients with diagnosed Zika virus infection. If Zika virus RNA was detected, we offered testing of serial
samples. We advised that samples be collected in sterile pots and transported at ambient temperature. We analyzed the samples by using the RNA extraction and rRT-PCR testing procedures described here, without modification.

Results
Since December 2013, nearly 2,500 Zika virus diagnostic molecular detection tests have been performed on travelers returning to the United Kingdom with possible Zika virus infection. As of October 5, 2016, a total of 116 persons, 55 of whom were males, had detectable Zika virus RNA in serum, plasma, or urine (23). Sixteen male patients (29.1%) submitted ≥1 semen sample (patients 1–16). In addition, 7 patients (patients 17–23) submitted semen samples after serologic diagnoses (i.e., detection of Zika virus IgM and IgG in serum but without detection of Zika virus RNA).

All patients had recently traveled from the Americas or Caribbean, except patient 1, who acquired Zika virus infection in the South Pacific in 2014. All patients reported a self-limiting, mild illness with fever and/or rash consistent with Zika virus infection (online Technical Appendix Tables 1 and 2, https://wwwnc.cdc.gov/EID/article/23/4/16-1692-Techapp1.pdf). None reported hematospermia.

We detected Zika virus RNA in ≥1 semen sample from 10 (62.5%) of the 16 patients with rRT-PCR–diagnosed infection and from 2 (28.6%) of the 7 patients with serologically diagnosed infection. For the 10 patients who had a positive initial blood or urine sample and a subsequent positive semen sample, the median cycle threshold (Ct) value was significantly lower for semen samples (Ct 27.3) than for acute-phase diagnostic serum, plasma, or urine samples (Ct 34.1; p = 0.01 by sign test).

Further semen samples were provided by 8 of the 12 Zika virus–positive patients (Figure). A series of samples sufficient to demonstrate seminal clearance of Zika virus RNA was available for 4 patients (2,5,9,10). Patient 5 demonstrated the longest time to clearance (from day 92 to day 131). For other patients from whom additional positive semen samples were received, Ct values increased consistently over time (i.e., genome copy number fell). The day 167 semen sample of patient 8 repeatedly demonstrated a subthreshold curve in the rRT-PCR test, suggesting evidence of Zika virus RNA at the assay detection limit. This patient was taking immunosuppressive drug therapy when infected (disease-modifying antirheumatic drugs [discontinued after his diagnoses with Zika virus infection] and oral steroids). No other patients were known to have immunosuppression.

Zika virus RNA was undetectable in semen samples from 5 of the 16 patients with rRT-PCR–diagnosed infection (31.3%); results were indeterminate (subthreshold) for 1 patient (6.3%). All 6 patients subsequently seroconverted for Zika virus IgG (data not shown). The indeterminate result occurred in the only patient who had undergone a vasectomy (day 16 sample). Zika virus RNA was also undetectable in the semen of 5 (71.4%) of the 7 patients with serologically diagnosed infection. Although Zika virus infection was not definitively confirmed by molecular testing in any of these 5 patients, laboratory tests excluded recent chikungunya or dengue infection (online Technical Appendix Table 2).

![Figure](image.png)

**Figure.** Cycle threshold (Ct) values of semen samples analyzed to determine presence and persistence of Zika virus RNA in semen, United Kingdom, 2016. All references to days indicate days after onset of symptoms. The dotted line represents the limit of detection for the assay. The lines represent implied decay rates based on longitudinal data; however, they should not be used to infer exact data between analyzed samples. In particular, the point at which viral RNA became undetected cannot be accurately inferred from the curves for patients 5, 8, 9, and 10. Patient 6 had a previous vasectomy, and patient 8 was receiving immunosuppressive drug therapy at the time of sampling. IND, indeterminate; NA, not available.
Of the 15 patients with rRT-PCR–confirmed infection in whom previous dengue serostatus could be assessed at the time of their initial Zika virus diagnosis (because no potentially cross-reactive Zika virus IgG was detectable at that time), only 3 had serologic evidence of previous dengue virus infection. Two of these patients (patients 3 and 6) did not have Zika virus RNA in subsequent semen samples (online Technical Appendix Table 1).

We attempted isolation of viable virus from all initial positive semen samples, with 1 successful isolation (day 13 sample from patient 7, C, 24). We attempted virus isolation in Vero and C6/36 cells; we observed propagation only in C6/36 cells for the original sample, although C6/36 infected supernatant was capable of infecting Vero cells and produced a cytopathic effect. We deposited the complete genome for this isolate in GenBank (accession no. KX673530) (24).

Discussion

Although persistence of Zika virus in serum and plasma appears to be transient, our data show that Zika virus RNA is frequently detectable in semen for several weeks to months after recovery from symptomatic infection. Zika virus RNA persistence in semen is not consistent; 10 (43.5%) of the 23 patients we tested lacked detectable Zika virus RNA in semen on the first sample (all but 1 tested within 28 days after symptom onset). Our detection of Zika virus RNA in early semen samples from 12 (52.2%) of 23 infected patients is similar to the detection of viral RNA in 50% of case-patients in small-number Belgian (17) and French (18) series.

We observed no obvious differences in terms of age, travel history, or symptoms between the patients with and without Zika virus RNA in our series, although detailed clinical information about ethnic origin, symptom severity or duration, and laboratory parameters, such as platelet count or C-reactive protein, were not collected. Sample degradation probably could not explain the negative results because the time from sample collection to testing was shorter on average for negative samples than for samples yielding positive results (data not shown).

One patient with an indeterminate rRT-PCR result for his initial (day 16) semen sample was reported to have had a vasectomy; ongoing viral replication might have been occurring in the urogenital tract. A recent publication reported Zika virus RNA in the ejaculate of a vasectomized man 96 days after onset of symptoms in addition to infectious virus cultured at 69 days (25), suggesting that previous vasectomy does not necessarily preclude the possibility of viral RNA or infectious virions in the semen.

It has been hypothesized that previous dengue infection might drive greater Zika virus replication through the mechanism of antibody-dependent enhancement; this process has been observed in vitro (26,27). However, our data indicate that this process cannot be invoked as a potential sole explanation for seeding of infection in the urogenital tract; among the 9 patients with Zika virus RNA in their semen for whom dengue serostatus at the time of Zika virus infection could be determined, only 1 (patient 10) had serologic evidence of previous dengue virus infection. Our data are insufficient to allow speculation as to whether an altered immune response associated with previous dengue infection might protect against viral replication in the male urogenital tract.

Among the 12 patients in whom Zika virus RNA was detected in semen, all samples obtained within 28 days of symptom onset had C, values <30, indicative of high genome copy number. This observation is concordant with other reports (9,12,17,19,28–31) and suggests that the risk for sexual transmission is particularly high in the first few weeks after infection.

The specimens analyzed in this report were provided at the discretion of the patients, and the data are subject to limitations. Monitoring was inconsistent, and patients were lost to follow-up. Clearance of Zika virus RNA from semen was demonstrated for only 4 patients. In all other patients from whom serial Zika virus RNA–positive semen samples were received, the C, value increased over time, consistent with a fall in genome copy number, as has been observed previously (12,17,30,32). The patient with an indeterminate (subthreshold) result at 167 days (patient 8) was receiving immunosuppressive therapy. Because Zika virus is the only known arbovirus with evidence for human sexual transmission, we cannot compare the persistence of Zika virus RNA or infectious virions in semen to similar viruses. Although the presence of Zika virus in semen is presumed to be attributable to viral replication at an immunoprivileged site within the urogenital tract, the cell type in which replication occurs is not currently known. In a mouse model, viral RNA was detected in the testes, in spermatogonia, primary spermatocytes, and Sertoli cells (33).

Detection of Zika virus RNA in semen samples does not necessarily indicate the presence of infectious virus. We attempted in vitro isolation from all positive samples; only 1 sample (day 13 sample from patient 7, C, 24) yielded replicating virus. Isolation from samples with similar C, values was unsuccessful, highlighting the inconsistency for this technique at present. The inability to isolate virus cannot be taken to indicate the absence of infectious virus until more is known about the intricacies of virus isolation from semen. Although we have been unable to isolate virus in tissue culture consistently from semen samples, it is striking that all recognized transmission events to date have occurred relatively soon after infection in the male index patient (8–13,34). The longest published interval for sexual transmission after symptom onset is 32–41 days (14). Even if methodology for reliably isolating Zika virus
from semen samples is established, it will be difficult to determine whether semen samples with Zika virus RNA detected at lower copy numbers contain infectious virions.

The current World Health Organization (WHO) guidelines advise that male and female travelers should adopt safer sex practices or consider abstinence to reduce the risk for sexual transmission for 6 months after leaving a country with ongoing Zika virus transmission (35). This recommendation was a conservative estimate for symptomatic men given the maximum reported persistence of Zika virus RNA in semen (62 days) at the time the WHO guidelines were issued (May 2016). Our data, together with other recent case reports (12,18–20,25,32,36), show that Zika virus RNA is sometimes detectable beyond 62 days, with the maximum period of RNA detection observed to date being approximately 6 months (20). However, our understanding of the dynamics for virus or viral RNA clearance are still nascent, and further data are required to assess the validity of current recommendations.

Currently, we lack knowledge of viral persistence in semen. More data, especially from larger systematic studies, are urgently needed to support evidence-based policies to prevent sexual transmission of Zika virus. In the meantime, testing of semen from symptomatic men >8 weeks after leaving a Zika-affected area, as suggested by WHO (35), might be valuable for assessing individual risk and for contributing to global data.

Acknowledgments

We thank the staff of the Rare and Imported Pathogens Laboratory for processing routine clinical samples. We also thank the staff of the Diagnostic Support Group at Public Health England–Porton for assistance in processing semen samples. The authors also gratefully acknowledge the patients who volunteered semen samples and their clinicians. In addition, the authors acknowledge the work of Lisa Ottowell and Victoria Graham in performing in vitro isolation work.

This work was funded by Public Health England.

Dr. Atkinson is a molecular virologist at Public Health England, United Kingdom. His research interests focus on the design and development of molecular detection assays for rare and emerging high-consequence human pathogens.

References

1. World Health Organization. Zika situation report, 29 September 2016 [cited 2016 Oct 9]. http://www.who.int/emergencies/zika-virus/situation-report/29-september-2016/en
2. Duffy MR, Chen T-H, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360:2536–43. http://dx.doi.org/10.1056/NEJMoa0805715
3. Brasil P, Calvet GA, Siqueira AM, Wakimoto M, de Sequeira PC, Nobre A, et al. Zika virus outbreak in Rio de Janeiro, Brazil: clinical characterization, epidemiological and virological aspects. PLoS Negl Trop Dis. 2016;10:e0004636. http://dx.doi.org/10.1371/journal.pntd.0004636
4. Cerbono-Jet M, Mesquita EC, Souza TML, Parreira V, Wittlin BB, Durovni B, et al. Clinical manifestations of Zika virus infection, Rio de Janeiro, Brazil, 2015. Emerg Infect Dis. 2016;22:1318–20. http://dx.doi.org/10.3201/eid2207.160375
5. Thomas DL, Sharp TM, Torres J, Armstrong PA, Munoz-Jordan J, Ryff KR, et al. Local transmission of Zika virus—Puerto Rico, November 23, 2015–January 28, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:154–8. http://dx.doi.org/10.15585/mmwr.mm6506e2
6. World Health Organization. Zika causality statement [cited 2016 Oct 9]. http://www.who.int/emergencies/zika-virus/causality/en
7. Johansson MA, Mier-y-Teran-Romero L, Reehuis J, Gilboa SM, Hills SL. Zika and the risk of microcephaly. N Engl J Med. 2016;375:1–4. http://dx.doi.org/10.1056/NEJMmp1605367
8. Deckard DT, Chung WM, Brooks JT, Smith JC, Woldai S, Hennessey M, et al. Male-to-male sexual transmission of Zika virus—Texas, January 2016. MMWR Morb Mortal Wkly Rep. 2016;65:372–4. http://dx.doi.org/10.15585/mmwr.mm6514a3
9. D’Ortenzio E, Motheron S, Yazdanpanah Y, de Lamballerie X, Hubert B, Piorkowski G, et al. Evidence of sexual transmission of Zika virus. N Engl J Med. 2016;374:2195–8. http://dx.doi.org/10.1056/NEJMmc1604449
10. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Trivassos da Rosa A, Haddock AD, et al. Probable non-vector-borne transmission of Zika virus, Colorado, USA. Emerg Infect Dis. 2011;17:880–2. http://dx.doi.org/10.3201/eid705.101939
11. Frank C, Cadar D, Schlaphof A, Neddersen N, Günther S, Schmidt-Chanasit J, et al. Sexual transmission of Zika virus in Germany, April 2016. Euro Surveill. 2016;21:30252. http://dx.doi.org/10.2807/1560-7917.ES.2016.21.23.30252
12. Harrower J, Kiedrzyński T, Baker S, Upton A, Rahnama F, Sherwood J, et al. Sexual transmission of Zika virus and persistence in semen, New Zealand, 2016. Emerg Infect Dis. 2016;22:1855–7. PubMed https://dx.doi.org/10.3201/eid2210.160951
13. Hills SL, Russell K, Hennessey M, Williams C, Oster AM, Fischer M, et al. Transmission of Zika virus through sexual contact with travelers to areas of ongoing transmission—continental United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:215–6. http://dx.doi.org/10.15585/mmwr.mm6508e2
14. Turnel JM, Abgueguen P, Hubert B, Vandamme YM, Maquart M, Le Guillou-Guillemette H, et al. Late sexual transmission of Zika virus related to persistence in the semen. Lancet. 2016;387:2501. http://dx.doi.org/10.1016/S0140-6736(16)30775-9
15. Brooks RB, Carlos MP, Myers RA, White MG, Bobo-Lenoci T, Aplan D, et al. Likely sexual transmission of Zika virus from a man with no symptoms of infection—Maryland, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:915–6. http://dx.doi.org/10.15585/mmwr.mm6534e2
16. Freour T, Mirallié S, Barrière P, Maquart M, Haddaoui S, et al. Sexual transmission of Zika virus in an entirely asymptomatic couple returning from a Zika epidemic area, France, April 2016. Euro Surveill. 2016;21:30254. http://dx.doi.org/10.2807/1560-7917.ES.2016.21.23.30254
17. Huitus R, De Smet B, Ariën K, Van Esbroeck M, de Jong B, Botteiué E, et al. Kinetics of Zika virus persistence in semen. Bull World Health Organ Zika Open. 2016 Jul 6. http://dx.doi.org/10.2471/BLT.16.181370
18. Mansuy JM, Suberbielle E, Chapuy-Regaud S, Mengelle C, Bujan L, Marchou B, et al. Zika virus in semen and spermatozoa. Lancet Infect Dis. 2016;16:1106–7. http://dx.doi.org/10.1016/S1473-3099(16)30336-X
19. Barzon L, Pacenti M, Berto A, Sinigaglia A, Franchin E, Lavezzo E, et al. Isolation of infectious Zika virus from saliva and prolonged viral RNA shedding in a traveller returning from the
Zika virus is spread to people through mosquito bites. Outbreaks of Zika have occurred in areas of Africa, Southeast Asia, the Pacific Islands, and the Americas. Because the Aedes species of mosquitoes that spread Zika virus are found throughout the world, it is likely that outbreaks will spread to new countries. In May 2015, the Pan American Health Organization issued an alert regarding the first confirmed Zika virus infection in Brazil. In December 2015, Puerto Rico reported its first confirmed Zika virus case.

Address for correspondence: Emma J. Aarons, Rare and Imported Pathogens Laboratory, Public Health England – Porton, Salisbury, Wiltshire SP4 0JG, United Kingdom; email: emma.aarons@phe.gov.uk
Presence and Persistence of Zika Virus RNA in Semen, United Kingdom, 2016

Technical Appendix

**Technical Appendix Table 1.** Characteristics of patients with real-time RT-PCR–confirmed Zika virus infection who were evaluated to determine presence and persistence of Zika virus RNA in semen samples, United Kingdom, 2016*

| Patient | Travel history | Initial Zika virus diagnosis sample | Initial flavivirus serostatus | First semen sample |
|---------|----------------|-----------------------------------|------------------------------|-------------------|
|         |                | Day PSO | Sample type | Zika virus test result | Zika virus antibodies† | Dengue IgG‡ | Previous dengue | Zika virus RNA result |
| 1       | Cook Islands  | Day 3   | Serum (No urine) | RNA detected Ct 35 | Not tested | IND | ND | Day 27 | Detected Ct 29 |
|         | Feb 2014      |         |              |                  |                      |          |      |        |            |
| 2       | Colombia      | Day 1   | Serum (No urine) | RNA detected Ct 37.6 | IgM not detected IgG not detected | Not detected | No | Day 26 | Detected Ct 27.1 |
|         | Dec 2015      |         |              |                  |                      |          |      |        |            |
| 3       | Colombia      | Day 3   | Serum (No urine) | RNA detected Ct 37.3 | IgM not detected IgG not detected | Detected | Yes | Day 23 | Not detected |
|         | Dec 2015      |         |              |                  |                      |          |      |        |            |
| 4       | Venezuela     | Day 1   | Urine§       | RNA detected Ct 30.7 | IgM not detected IgG not detected | Not detected | No | Day 10 | Not detected |
|         | Jan 2016      |         |              |                  |                      |          |      |        |            |
| 5       | Brazil        | Day 3   | Urine§       | RNA detected Ct 34.3 | IgM not detected IgG not detected | Not detected | No | Day 21 | Detected Ct 21.3 |
|         | Feb 2016      |         |              |                  |                      |          |      |        |            |
| 6       | Barbados      | Day 5   | Plasma (No urine) | RNA detected Ct 32.9 | IgM not detected IgG not detected | Detected | Yes | Day 16 | IND (sub-threshold only) |
|         | Mar 2016      |         |              |                  |                      |          |      |        |            |
| 7       | Guadeloupe    | Day 2   | Plasma (No urine) | RNA detected Ct 30.1 | IgM not detected IgG not detected | Not detected | No | Day 13 | Detected Ct 24.0 |
|         | Apr 2016      |         |              |                  |                      |          |      |        |            |
| 8       | Brazil        | Day 1   | Plasma (No urine) | RNA detected Ct 39.6 | IgM not detected IgG not detected | Not detected | No | Day 13 | Detected Ct 19.2 |
|         | Apr 2016      |         |              |                  |                      |          |      |        |            |
| 9       | Brazil        | Day 2   | Plasma (No urine) | RNA detected Ct 37.8 | IgM not detected IgG not detected | Not detected | No | Day 9  | Detected Ct 27.5 |
|         | May 2016      |         |              |                  |                      |          |      |        |            |
| 10      | Dominican     | Day 1   | Serum & urine | RNA detected Ct 37.2 in serum Ct 30.4 in urine | IgM not detected IgG not detected | Detected | Yes | Day 14 | Detected Ct 21.6 |
| Republic | Jun 2016     |         |              |                  |                      |          |      |        |            |
| 11      | Grenada       | Day 3   | Urine§       | RNA detected Ct 31.1 | IgM Detected IgG not detected | Not detected | No | Day 22 | Not detected |
|         | Jun 2016      |         |              |                  |                      |          |      |        |            |
| 12      | Grenada       | Day 4   | Urine§       | RNA detected Ct 30.8 | IgM INDET IgG not detected | Not detected | No | Day 12 | Not detected |
|         | Jun 2016      |         |              |                  |                      |          |      |        |            |
| 13      | Jamaica       | Day 3   | Plasma (No urine) | RNA detected Ct 32.4 | IgM not detected IgG not detected | Not detected | No | Day 50 | Detected Ct 29.5 |
|         | Jun 2016      |         |              |                  |                      |          |      |        |            |
| 14      | Mexico        | Day 6   | Urine§       | RNA detected Ct 26.9 | IgM Detected IgG not detected | Not detected | No | Day 63 | Detected Ct 37.7 |
|         | Jul 2016      |         |              |                  |                      |          |      |        |            |
| 15      | Mexico        | Day 2   | Plasma (No urine) | RNA detected Ct 37.7 | IgM not detected IgG not detected | Not detected | No | Day 10 | Not detected |
|         | Jul-Aug 2016  |         |              |                  |                      |          |      |        |            |
determine presence and persistence of Zika virus RNA in semen

Technical Appendix Table 2. Characteristics of patients with serologically diagnosed Zika virus infection who were evaluated to determine presence and persistence of Zika virus RNA in semen samples, United Kingdom, 2016*

| Patient | Travel history | Initial Zika virus diagnostic sample | Initial flavivirus serostatus | First semen sample |
|---------|----------------|------------------------------------|------------------------------|--------------------|
|         |                | Day PSO | Sample type | Zika virus test result | Dengue IgM† | Previous dengue | Day PSO | Zика virus RNA result |
| 16      | Barbados       | Day 3   | Serum (No urine) | RNA detected Ct 33.8 | IgM not detected | Not detected | No | Day 38 | Detected Ct 31.8 |
|         | Aug 2016       |         |             |                     | IgG not detected |                     |     |        |                   |

* Ct, cycle threshold; IND, indeterminate; ND, not determined; PSO, post symptom onset.
† Euroimmun Anti-Zika Virus ELISA (IgM) and Euroimmun Anti-Zika Virus ELISA (IgG).
‡ Panbio dengue IgM capture ELISA and dengue IgG indirect ELISA.
§ Panbio dengue IgM capture ELISA and dengue IgG indirect ELISA.
¶ Euroimmun yellow fever IgG IFA.
†‡ All samples also tested for chikungunya virus, no positives detected.
** This patient seroconverted; Zika IgM and IgG antibodies were undetectable in a sample taken on Day 4, but IgM was strongly positive on Day 6 and Day 14, and IgG became weakly positive on Day 14.